These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9510501)

  • 41. Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.
    Shnyder SD; Cooper PA; Millington NJ; Pettit GR; Bibby MC
    Int J Oncol; 2007 Aug; 31(2):353-60. PubMed ID: 17611692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
    Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
    Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10.
    Prokopiou EM; Cooper PA; Pettit GR; Bibby MC; Shnyder SD
    Mol Med Rep; 2010; 3(2):309-13. PubMed ID: 21472238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium.
    Kraft AS; Adler V; Hall P; Pettit GR; Benjamin WH; Briles DE
    Cancer Res; 1992 Apr; 52(8):2143-7. PubMed ID: 1559218
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.
    McGown AT; Jayson G; Pettit GR; Haran MS; Ward TH; Crowther D
    Br J Cancer; 1998; 77(2):216-20. PubMed ID: 9460991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
    Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
    Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
    Beck FW; Al-Katib AM; Ahmad I; Wall NR; Liu KZ; Mantsch HH; Mohammad RM
    Int J Mol Med; 2000 Apr; 5(4):341-7. PubMed ID: 10719048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the antitumor activity of bryostatins 1, 5, and 8.
    Kraft AS; Woodley S; Pettit GR; Gao F; Coll JC; Wagner F
    Cancer Chemother Pharmacol; 1996; 37(3):271-8. PubMed ID: 8529289
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
    Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
    Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy.
    Nabha SM; Mohammad RM; Wall NR; Dutcher JA; Salkini BM; Pettit GR; Al-Katib AM
    Anticancer Drugs; 2001 Jan; 12(1):57-63. PubMed ID: 11272287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
    Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
    Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE.
    Woyke T; Pettit GR; Winkelmann G; Pettit RK
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3580-4. PubMed ID: 11709343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc.
    Turner T; Jackson WH; Pettit GR; Wells A; Kraft AS
    Prostate; 1998 Feb; 34(3):175-81. PubMed ID: 9492845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
    Philip PA; Rea D; Thavasu P; Carmichael J; Stuart NS; Rockett H; Talbot DC; Ganesan T; Pettit GR; Balkwill F
    J Natl Cancer Inst; 1993 Nov; 85(22):1812-8. PubMed ID: 8230261
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model.
    Hayun M; Okun E; Hayun R; Gafter U; Albeck M; Longo DL; Sredni B
    Leukemia; 2007 Jul; 21(7):1504-13. PubMed ID: 17508000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft.
    Lee SC; Huang MQ; Nelson DS; Pickup S; Wehrli S; Adegbola O; Poptani H; Delikatny EJ; Glickson JD
    NMR Biomed; 2008 Aug; 21(7):723-33. PubMed ID: 18384181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful treatment of murine melanoma with bryostatin 1.
    Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
    Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Boise L; Westin E; Howe C; Pettit GR; Turner A; McCrady C
    Biochem Pharmacol; 1991 Jul; 42(4):853-67. PubMed ID: 1867641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.
    Grant S; Pettit GR; Howe C; McCrady C
    Leukemia; 1991 May; 5(5):392-8. PubMed ID: 2033960
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.
    Grant S; Traylor R; Bhalla K; McCrady C; Pettit GR
    Leukemia; 1992 May; 6(5):432-9. PubMed ID: 1593908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.